ANDA 91563, held by Chartwell Molecules. Disulfiram.
As of Nov 16, 2026, ANDA 91563 (Disulfiram), held by Chartwell Molecules, was first approved by FDA on Dec 31, 2012, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Disulfiram is an aid in the management of selected chronic alcohol patients who want to remain in a state of enforced sobriety so that supportive and psychotherapeutic treatment may be applied to best advantage. Disulfiram is not a cure for alcoholism. When used alone, without proper motivation and supportive therapy, it is unlikely that it will have any substantive effect on the drinking pattern of the chronic alcoholic.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 31, 2012 | Original application | Approved | None posted |
| Disulfiram250MG · tablet;oral | Disulfiram | Rx |
| Disulfiram500MG · tablet;oral | Disulfiram | Rx |
| Nov 2, 2021 | Supplement 7Manufacturing | Approved | None posted |
| Dec 31, 2012 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters